AstraZeneca Requests FDA Approval for Self-Administered Nasal Flu Vaccine
AstraZeneca submitted a request for the FDA on Wednesday to approve a self-administered nasal flu vaccine for people ages two to 49 years old. The vaccine, FluMist, would become the first at-home vaccine that would allow anyone 18 years of age and older to administer it to themselves and those underage.
If approved, at-home FluMist would be used similarly to other nose sprays, by injecting it into the nasal cavity, “providing a convenient new choice for individuals and families who want to protect their loved ones against the flu,” AstraZeneca said in a press release. FluMist is already an approved flu vaccine, but it currently can only be administered by a health care professional.
Read more
Toyota’s Chairman Is Having His ‘I Told You So Moment’ About EVs
New House Speaker Mike Johnson Wants Women to Pop Out 'Able-Bodied Workers' to Fund Social Security
Peter Parker Can’t Do The ‘Wakanda Forever’ Salute In Spider-Man 2
She says that the company is confident that a home FluMist vaccine will be easy to use and would be shipped with specific directions on how to administer the nasal spray. Details surrounding the packaging and shipment process are not yet available. AstraZeneca says it expects it to be available in the U.S. for the 2024-2025 flu season.
The company did not immediately respond to Gizmodo’s request for more information about the cost of an at-home FluMist vaccine and its potential coverage by insurers.
More from Gizmodo
At $18,500, Is This 2014 BMW 750Li xDrive A Tech-Laden Bargain?
Dancing With The Stars casting Sean Spicer is a big part of why Tom Bergeron left
This Decrepit Ship Could Spark A Conflict Between The U.S. And China
Sign up for Gizmodo's Newsletter. For the latest news, Facebook, Twitter and Instagram.
